Abstract:Objective:To evaluate safety and efficacy of bevacizumab(AVASTIN ) plus chemotherapy for the treatment of gastrointestinal cancer patients.Methods:A retrospective study of 77 gastrointestinal(GI ) cancer patients treated with bevacizumab plus chemotherapy was performed.Patient information collected included previous disease history,signs,synptom and homological and biochemical profiles.Patients were followed up for eight weeks after the last treatment or death.Statistical tests were used for subgroup analysis. Results:All patients had locally advanced or metastatic GI cancer,who were not suitable for surgery.Their pathological diagnosis was adenocarcinoma,mucinous adenocarcinoma,or signet-ring cell carcinoma.Among these patients,there were 65 colorectal cancer patients and 12 gastric cancer patients.There were 36 male and 41 female patients with the median age of 49 years(26-76 years ).The incidence of all adverse events among these 77 patients was 89.6%(69/77 ).The incidence of adverse event(AE ) with grade 3/4 and SAE was 26.0%(20/77 ).Stratified analysis on AE with grade of 3 / 4 and SAE indicated that the incidence was 44.4%(4/9 ) in old-age group (65 years old and older ) and 23.5%(16 / 68 ) in young-age group(younger than 65 years old ).The incidence was 25%(9/36 ) in male patients and 26.0%(11 / 41 ) in female patients.The incidence was 30.6%(11 / 36 ) in the first-line therapy group and 22.0%(9/41 ) in the second or later line therapy group.There was no statistical difference between each group.For patients treated with bevacizumab plus two-agent chemotherapy,the incidence of AE was 50%～60%and most of them were hematological toxicity and gastrointestinal discomforts (such as nausea and vomiting).For bevacizumab combining with single-agent chemotherapy,the incidence of AEs was 5%～8%.There were 4 cases of hypertension,2 cases of proteinuria,4 cases of bleeding,and 2 cases of delayed wound healing.There was 1 case of S AEs, which might be related to the studied drug.Conclusion:The bevacizumab safety profile in this study was consistent with its safety profile in other clinical trials.The incidence of AE was not correlated with chemotherapy,gender or age.The bevacizumab related AE was rare and not accumulative with cytotoxic drug(s ).

Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer

Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups

Bevacizumab-associated Bowel Perforation：a Case Report and Literature Review

Spontaneous massive duodenal perforation after ovarian cancer treatment with bevacizumab

Bevacizumab is associated with a higher gastrointestinal/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy

Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database

Spontaneous acalculous gallbladder perforation in a man secondary to chemotherapy and radiation: A rare case report.

Rare Case of Endoscopic Treatment for Bevacizumab-Related Gastric Perforation in a Patient with Ovarian Cancer

Bevacizumab for the Treatment of Gammaknife Radiosurgery-Induced Brain Radiation Necrosis

Bevacizumab for the treatment of metastatic colorectal cancer complicated by abdominal aortic aneurysm and mural thrombus: a case report

Severe Esophageal Bleeding in Colorectal Cancer Due to Antitumor Therapy: A Case Report

Clinical Study on the Safety of Bevacizumab in the Treatment of Patients with Advanced Colorectal Cancer

Safety of Bevacizumab with Chemotherapy in Treating Gastrointestinal Cancer

Bevacizumab-Related Surgical Site Complication Despite Primary Tumor Resection in Colorectal Cancer Patients

Celiac trunk aortic dissection induced by bevacizumab therapy for rectal cancer: A case report

A case report of vesicovaginal fistula following Bevacizumab without pelvic disease and radiochemotherapy

Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis

Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)

Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer.

Risk of Gastrointestinal Perforation in Cancer Patients Treated with Aflibercept: a Systematic Review and Meta-Analysis

Bevacizumab-induced esophageal pleural fistula during maintenance therapy without radiation in lung cancer